Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma

Blood Cancer J. 2023 Oct 12;13(1):156. doi: 10.1038/s41408-023-00927-2.

Authors

Affiliations

¹ Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pjain@mdanderson.org.
² BostonGene Corporation, Boston, MA, USA.
³ Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Humans
Lymphoma, Mantle-Cell* / drug therapy
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases
Tumor Microenvironment

Substances

Protein-Tyrosine Kinases
Protein Kinase Inhibitors

Grants and funding